Pharmaceutical Executive
Pharmaceutical Executive
Pharmaceutical Executive Podcast
Pharmaceutical Executive Daily: September 17, 2025
2 minutes Posted Sep 17, 2025 at 7:50 pm.
0:00
2:36
Download MP3
Show notes
In today’s Pharmaceutical Executive Daily, we cover Lilly’s orforglipron as a prime candidate for FDA fast-track approval, Merck and Daiichi Sankyo’s breakthrough therapy designation for R-DXd in ovarian cancer, and Novo Nordisk’s EU approval of Rybelsus for reducing cardiovascular risk.